⚠️ Serious warning: Nothing on this website is approved by any physician. Doz is only a tool to help physicians and to search drugs easily. Taking medicines without medical supervision can be fatal.

Ceftaroline fosamil

سفتارولین

⚠ Unverified

🦠 Antiinfectives For Systemic UseFifth-generation cephalosporin (anti-MRSA)

🤰 Pregnancy:Use with caution 👶 Children:Use with caution 👴 Older adults:Use with caution 🇮🇷 Not found in Iran list ⛔ 1 contraindications 🇺🇸 FDA approved (NDA) NDA200327 ATC J01DI02

Market / country: 🇺🇸 USA

Teflaro (US)

🧮 Dose calculator

Disease / regimen

Skin and skin structure infection · Regimen source: FDA Teflaro · 2.1, Table 1

• Infuse over 5–60 min. FDA Teflaro · 2.1

Formulation

Age *

Weight (kg) (optional)

Enter age (weight is optional for this regimen).

🛡️ Safety & information

Contraindications

⛔ Serious hypersensitivity to ceftaroline or other cephalosporins. FDA Teflaro · 4

Warnings

• Hypersensitivity (beta-lactam cross-reactivity); C. difficile diarrhoea; neurological reactions (encephalopathy, seizures) especially in renal impairment; positive Coombs test. FDA Teflaro · 5

Renal adjustment

• eGFR < 51: CrCl ≤50: reduce dose per label table. FDA Teflaro · 2.3

Formulations

600 mg vial — powder for injection 🇺🇸 USA FDA Teflaro · 3
400 mg vial — powder for injection 🇺🇸 USA FDA Teflaro · 3

👥 Special populations

🤰 PregnancyUse with caution
Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Teflaro · 8.1
“Risk Summary There are no adequate studies with Teflaro in pregnant women that informed any drug associated risks.”
🤱 BreastfeedingNo data
The source for this drug has no section for this group.
👶 ChildrenUse with caution
The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Teflaro · 8.4
“The safety and effectiveness of Teflaro in the treatment of ABSSSI have been established in pediatric patients (at least 34 weeks gestational age and 12 days postnatal age).”
👴 Older adultsUse with caution
Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Teflaro · 8.5
“Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in this age group and it may be useful to monitor renal function.”
⚥ Females & males of reproductive potentialNo data
The source for this drug has no section for this group.

🔗 Reference links

FDA (approval record)NDA200327
DailyMed (FDA label)FDA Teflaro
MedlinePlus (NIH)Ceftaroline Injection
WHO ATC/DDDJ01DI02
Darooyab (Iran)Ceftaroline

🇮🇷 Not found in Iran list Darooyab · G-4896/Ceftaroline

Darooyab lists no registered dosage form or brand for this drug. This does not prove it is unavailable.

📚 Reference status for this drug

Shows which sources have references recorded for this drug and which do not.

FDA label (DailyMed)✅ Present
FDA Teflaro · 3 FDA Teflaro · 2.1, Table 1 FDA Teflaro · 2.1 FDA Teflaro · 2.2, Table 2 FDA Teflaro · 2.2 FDA Teflaro · 4 FDA Teflaro · 5 FDA Teflaro · 2.3 FDA Teflaro · 8.1 FDA Teflaro · 8.4 FDA Teflaro · 8.5 FDA Teflaro · SPL approval / marketing category
UK SmPC (eMC / MHRA)❌ Not present
Published guideline❌ Not present
Licensed reference (medical school)❌ Not present
Iranian leaflet (IFDA)❌ Not present
Pharmacy website (secondary, unreliable)✅ Present
Darooyab · G-4896/Ceftaroline
Clinical review⚠ Unverified